Render Target: STATIC
Render Timestamp: 2024-11-21T13:51:42.133Z
Commit: 5c4accf06eb7154018ba3f54329c7590f97f534a
XML generation date: 2024-09-30 02:00:06.758
Product last modified at: 2024-11-12T18:45:10.232Z
1% for the planet logo
PDP - Template Name: Monoclonal Antibody
PDP - Template ID: *******c5e4b77
R Recombinant
Recombinant: Superior lot-to-lot consistency, continuous supply, and animal-free manufacturing.

CCL3/MIP-1α (F3I3P) Rabbit mAb #43710

Filter:
  • WB

    Supporting Data

    REACTIVITY H
    SENSITIVITY Endogenous
    MW (kDa) 10
    Source/Isotype Rabbit IgG
    Application Key:
    • WB-Western Blotting 
    Species Cross-Reactivity Key:
    • H-Human 

    Product Information

    Product Usage Information

    Application Dilution
    Western Blotting 1:1000

    Storage

    Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/mL BSA, 50% glycerol, and less than 0.02% sodium azide. Store at –20°C. Do not aliquot the antibody.

    Protocol

    Specificity / Sensitivity

    CCL3/MIP-1α (F3I3P) Rabbit mAb recognizes endogenous levels of total CCL3/MIP-1α protein. This antibody does not cross-react with CCL4 or CCL18 proteins.

    Species Reactivity:

    Human

    Source / Purification

    Monoclonal antibody is produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Pro43 of human CCL3/MIP-1α protein.

    Background

    Chemokine (C-C motif) ligand 3 (CCL3), also known as macrophage inflammatory protein-1α (MIP-1α), is a 10 kDa member of the C-C or β family of chemokines that play key roles in immune surveillance, inflammation, and infection (1). CCL3 shares 68% amino acid identity with CCL4 (MIP-1β) and 94% amino acid identity with LD78β (1). CCL3 is produced by activated monocytes, activated macrophages, NK cells, and T cells (1). There are two receptors for CCL3: CCR1 and CCR5 (1). CCL3 inhibits R5 HIV-1 infection by competing with the virus for its co-receptor, CCR5 (1). CCL3 possesses hematopoietic stem cell inhibitory activity, suppressing their proliferation, but has been shown to promote proliferation of more mature progenitors (2-4). CCL3 has been implicated in several forms of leukemia, in which malignant cells may lose responsiveness to CCL3 or produce high levels of CCL3 (2). CCL3 polymorphisms are associated with risk for the development of rheumatoid arthritis and ulcerative colitis (5,6). CCL3 expression is upregulated in the brains of patients with Alzheimer's disease (AD) with dementia, and reduced expression of CCL3 is observed in AD patients resilient to dementia (7).
    For Research Use Only. Not For Use In Diagnostic Procedures.
    Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.
    All other trademarks are the property of their respective owners. Visit our Trademark Information page.